Tuesday, December 10, 2019 San Antonio Breast Cancer Symposium Presentation Session Time Location Defining a cancer dependency map Workshop: Molecular Biology in 11:45 am - 1:45 pm Hemisfair Ballroom - William C. Hahn, MD, PhD Breast Oncology - Moderator: 3rd Level Dana-Farber Cancer Institute Carlos L. Arteaga, MD Design and analysis of window and Workshop: Developing Novel 11:45 am - 1:45 pm Stars at Night Ballroom - neoadjuvant trials Therapeutics in the Metastatic 3rd Level Meredith Regan, ScD Setting - Dana-Farber Cancer Institute Moderator: Virginia G. Kaklamani, MD UT Health San Antonio Neoadjuvant therapy for hormone Workshop: Multidisciplinary 3:45 pm - 5:15 pm Stars at Night Ballroom 1 - receptor positive breast cancer: Approaches to Optimizing 3rd Level Advances and challenges Surgical Therapy for Hormone Otto Metzger, MD Receptor Positive Breast Cancer Dana-Farber Cancer Institute – Moderator: Armando Giuliano, MD Cedars-Sinai Medical Center Surgical considerations AFTER Workshop: Multidisciplinary 3:45 pm - 5:15 pm Stars at Night Ballroom 1 - preoperative therapy for hormone Approaches to Optimizing 3rd Level receptor positive breast cancer Surgical Therapy for Hormone Tari Ann King, MD Receptor Positive Breast Cancer Dana-Farber Cancer Institute – Moderator: Armando Giuliano, MD Cedars-Sinai Medical Center Progression of disease and end of life: Workshop: Conversations on 3:45 pm - 5:15 pm Stars at Night Ballroom 3&4 - How to break bad news Tough Topics Surrounding 3rd Level Eric P. Winer, MD Cancer Care – Dana-Farber Cancer Institute Moderator: Susan Rafte Community Advocate, Baylor College of Medicine Breast Center Houston, TX Future directions in endocrine therapy for Workshop: Endocrine Therapy 3:45 pm - 5:15 pm Hemisfair Ballroom - advanced HER+/HER2- breast cancer in 2020 3rd Level Erica L. Mayer, MD, MPH Moderator: Mothaffar Rimawi, MD Dana-Farber Cancer Institute Baylor College of Medicine
Wednesday, December 11, 2019 San Antonio Breast Cancer Symposium Presentation Session Time Location Tucatinib vs placebo, both combined with GS 1-01 8:45 am Hall 3 capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB), Eric Winer, MD (senior author) [Fam-] trastuzumab deruxtecan (T-DXd; DS- GS1-03 9:15 am Hall 3 8201a) in subjects with HER2-positive meta- static breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01), Ian Krop, MD, PhD Tbcrc 033: A randomized phase II study of GS1-05 9:45 am Hall 3 adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzum- ab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) Sara Tolaney, MD, MPH Introduction Discussion CAREER DEVELOPMENT FORUM 12:00 - 12:05 pm Room 304 Eric Winer, MD - Room 304 Dana-Farber Cancer Institute Systemic therapy for breast cancer CLINICAL SCIENCE FORUM - 1:00 pm - 2:00 pm Stars at Night Ballroom 3&4 - brain metastases Frontiers in HER2 Positive 3rd Level Nancy U. Lin, MD Breast Cancer Dana-Farber Cancer Institute Moderator: Sibylle Loibl, MD German Breast Group Acquired activating mutations in RTKs con- GS2-02 3:30 pm Hall 3 fer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state Nikhil Wagle, MD , Dana-Farber Cancer Institute, senior author Improvements in long-term outcome for GS2-04 4:00 pm Hall 3 women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database Richard D. Gelber, PhD
Thursday, December 12, 2019 San Antonio Breast Cancer Symposium Presentation Session Time Location Targeting HER2 and DNA Repair SPOTLIGHT SESSION 4: 7:00 am – 9am Stars at Night Ballroom 1&2 - Chair: Ian Krop, MD, PhD 3rd Level Dana-Farber Cancer Institute Multiplatform analysis of matched primary GS3-07 11:15 am Hall 3 and metastatic breast tumors from the AURORA US Network Tari King, MD Dana-Farber Cancer Institute Essential Genes and Cistromes AACR DISTINGUISHED 11:30 am - 12:00 pm Hall 3 in Breast Cancer LECTURESHIP IN BREAST Myles Brown, MD CANCER RESEARCH Dana-Farber Cancer Institute Panel Q&A: Getting the Most from Your CAREER DEVELOPMENT FORUM 12:00 pm - 1:00 pm Room 304 Training Eric Winer, MD Panelist - Room 304 Tari A. King, MD CASE DISCUSSION 1 – Stars at 1:00 pm - 2:00 pm Stars at Night Ballroom 1&2 - Dana-Farber Cancer Center Night Ballroom 1&2 - 3rd Level 3rd Level Panelist Immunotherapy in breast cancer: MINI-SYMPOSIUM 1 2:15 pm - 3:15 pm Hall 3 enhancing response to checkpoint blockade Elizabeth A. Mittendorf, MD, PhD Dana-Farber Cancer Institute Brigham and Women’s Cancer Center
Friday, December 13, 2019 San Antonio Breast Cancer Symposium Presentation Session Time Location Cost and value SPOTLIGHT SESSION 10: Tox- 7:00 am - 9:00 am Stars at Night Ballroom 3&4 - Michael Hasset, MD, MPH icity, Tolerability & Cost - Chair: 3rd Level Discussant Katherine Reeder-Hayes, MD Dana-Farber Cancer Institute University of North Carolina Targeting the cell cycle - MINI-SYMPOSIUM 2 - 2:15 pm - 3:15 pm Hall 3 Beyond CDK4/6 inhibition Rinath Jeselsohn, MD Dana-Farber Cancer Institute A joint atlas of single-cell and bulk RNA-seq in GS6-04 4:00 pm Hall 3 metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment Nikhil Wagle, MD, Dana-Farber Cancer Institute, senior author
Recommend
More recommend
